Previous studies have shown that the combination of tacrolimus and mTOR inhibitors is safe and associated with a significantly better glomerular filtration rate during the first two years after LT [94,96,97], but its role in the prevention of HCC recurrence is controversial. This evidence concerns the gene MTOR and hepatocellular carcinoma.